National and Kapodistrian University of Athens
Η συχνότητα των πολυμορφισμών του γονιδίου της C - αντιδρώσας πρωτεΐνης και της ιντερλευκίνης 6 σε ασθενείς με σακχαρώδη διαβήτη τύπου 2 και η η συσχέτιση τους με τις επιπλοκές του διαβήτη
Abstract
dc:descriptionObjectives: Low grade inflammation is involved in the pathogenesis of atherosclerosis. Several studies have shown that C-reactive protein (CRP) contributes to the pathogenesis of diabetes mellitus type 2 (T2DM) and predicts its incidence. Genes encoding for inflammatory cytokines such as interleukin-6 (IL6) are candidates for predisposing to the risk of atherosclerosis. Subjects with T2DM are vulnerable to the development of micro and macrovascular disease. The aim of the present cross-sectional study was to evaluate the frequency of the adenine / guanine 3872 (A3872G) polymorphism on CRP gene and the guanine / cytosine 174 (174GC) polymorphism on IL6 gene and their impact on the prevalence of micro and macrovascular complications in patients with type 2 diabetes mellitus (T2DM). Methods: The study population consisted of 431 patients with DM2 and 311 healthy controls. The polymorphisms were detected by Polymerase Chain Reaction (PCR) and appropriate restriction enzyme digestion (HpyCH4III, SFANI, respectively). Creactive protein (mg/l) was assayed by particle-enhanced immunonephelometry. The presence of the vascular complications was based on detailed history, clinical and imaging criteria’s. Results: The genotype distribution in patients with T2DM was GG:52%, AG:27.2%, AA:20.8% for the CRP3872AG polymorphism and GG:49.1%, GC:26.8%, CC:24.1% for the IL6174GC polymorphism. The CRP3872AG polymorphism affected the risk for T2DM. The AA homozygotes had higher odds for T2DM than AG genotype in patients with T2DM in comparison with healthy individuals, AA:89(68.5) vs AG:116(61.4), (OR 2.432, CI 1.046-5.654, p=0.039). It also affected the presence of peripheral arterial disease (PAD) in patients with T2DM. The carriers of the ‘’A’’ allele had higher odds for PAD compared with GG homozygotes, (after adjustment for risk factors, probably due to significantly interactions with other co-existence vascular complications and the receiving treatment), (AG+AA):82(40.0) vs GG:76(34.2), (OR 1.622, 95%CI 1.029-2.536, p=0.037). In addition, the polymorphism affected the presence of diabetic foot. The AG genotype had significantly lower levels of hs-CRP (mg/l), and was protected from the presence of diabetic foot in comparison with GG homozygotes, AG:31(26.7) GG:84(37.8), (OR 0.562, 95%CI 0.322-0.983, p=0.043). The polymorphism had no impact on coronary artery disease (CAD), carotid artery disease, peripheral neuropathy, nephropathy, retinopathy (background or proliferative), any macro and/or microangiopathy, in patients with T2DM. The IL6- 174GC polymorphism affected the risk for T2DM. The GC genotype had lower odds for smoking, in patients with T2DM and lower odds for T2DM, than GG homozygotes, GC:110(52.9) vs GG: 202(60.3), (OR 0.562, 95%CI 0.337-0.938, p=0.027), as well as than CC homozygotes, CC:99(62.7) vs GC, (OR 1.901, 95%CI 1.010-3.579, p=0.047), in patients with T2DM in comparison with healthy individuals. It also affected the presence of any macroangiopathy, in patients with T2DM. The GC genotype as well as participants carrying the ‘’C’’ allele, were protected from the presence of any macrovascular complication than GG homozygotes, GC:47(42.7) vs GG:113(55.9), (OR 0.452, 95%CI 0.255-0.802, p=0.007), (GC+CC):95(45.5) vs GG, (OR 0.554, 95%CI 0.350-0.878, p=0.012). In addition, the polymorphism affected the presence of nephropathy, in patients with T2DM. The CC homozygotes had significantly lower albumin excretion (mg/24h) and were protected from the presence of nephropathy in comparison with the GC genotype, CC:11(11.1) vs GC:16(14.5) (OR 0.416, 95%CI 0.207-0.835, p=0.014). The polymorphism affected also the presence of retinopathy, in patients with T2DM. The CC homozygotes, although had significantly higher levels of LDL-C (mg/dl), were protected from the presence of retinopathy in comparison with GG homozygotes, CC:21(21.2) vs GG:60(29.7), (OR 0.476, 95%CI 0.239-0.948, p=0.035), as well as in comparison with the carriers of ‘’G’’ allele (only after adjustment for risk factors, probably due to significant interactions with co-existence of diabetic foot or the receiving treatment), CC vs (GG+GC):98(29.6), (OR 0.505, 95%CI 0.270-0.946, p=0.033). Finally, the polymorphism affected the presence of diabetic foot. The GC genotype had significantly higher levels of Tg (mg/dl) and albumin excretion (mg/24h) and longer duration of diabetes (years) and had higher odds for diabetic foot than the GG homozygotes, GC:45(40.9) vs GG:59(29.2), (OR 1.865, 95%CI 1.125-3.090, p=0.016). The carriers of ‘’C’’ allele had higher odds for diabetic foot in comparison with GG homozygotes, (only after adjustment for risk factors, probably due to significant interactions with co-existence of other vascular complications, neuropathy indexes and the receiving treatment), (GC+CC):78(37.3) vs GG, (OR 1.584, 95%CI 1.031-2.426, p=0.036). The polymorphism did not affect CAD, carotid artery disease, PAD, peripheral neuropathy, any micro or any macro and micro angiopathy, in patients with T2DM. Conclusions: The two studied polymorphisms were significantly partly associated, with T2DM and its macro and microvascular complications. The exact mechanisms of their biological impacts are still unknown. More studies are needed to evaluate their role in the pathogenesis and the complications of T2DM.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Παπαοικονόμου-Παπακωνσταντίνου, Σταυρούλα
- Papaoikonomou, Stavroula
Subjects
dc:subject × 16- Σακχαρώδης διαβήτης τύπου ΙΙ
- C - αντιδρώσα πρωτεΐνη
- Α3872G πολυμορφισμός
- Ιντερλευκίνη-6
- 174GC πολυμορφισμός
- Επιπλοκές διαβήτη
- Type 2 daibetes mellitus
- C - reactive protein
- A3872G polymorphism
- Interleukin - 6
- 174GC polymorphism
- DIABETIC COMPLICATIONS
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29985